# AstraZeneca’s Imfinzi did not meet the primary endpoint in KESTREL Phase III trial

- Link: https://www.directorstalkinterviews.com/astrazenecas-imfinzi-did-not-meet-the-primary-endpoint-in-kestrel-phase-iii-trial/412958853
- Published: 2021-02-05T07:23:37+00:00
- Author: Amilia Stone

**[AstraZeneca plc](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
updates on KESTREL Phase III trial of _Imfinzi_ with or without tremelimumab in 
the 1st-line treatment of recurrent or metastatic head and neck cancer.

The KESTREL Phase III trial for AstraZeneca’s _Imfinzi_ (durvalumab) did not meet
the primary endpoint of improving overall survival (OS) versus the EXTREME treatment
regimen (chemotherapy plus cetuximab), a standard of care, in the 1st-line treatment
of patients with recurrent or metastatic head and neck squamous cell carcinoma (
HNSCC) whose tumours expressed high levels of PD-L1. Also, the combination of _Imfinzi_
plus tremelimumab did not indicate an OS benefit in ‘all-comer’ patients, a secondary
endpoint.

The safety and tolerability profiles for _Imfinzi_ as a monotherapy and in combination
with tremelimumab were consistent with previous trials. The data will be shared 
in due course.

**HNSCC**

Nearly 750,000 patients were diagnosed with head and neck cancer around the world
in 2020.^(1) Two thirds of these patients are diagnosed in advanced stages, and 
more than half of those treated eventually relapse.^(2,3) Median survival for a 
patient with an uncurable or metastatic relapse remains under one year.^(3) More
than 90% of all head and neck cancers start in the squamous cells that line the 
mouth, nose and throat and are called head and neck squamous cell carcinomas.^(4)

**KESTREL**

The KESTREL Phase III trial was a randomised, open-label, multi-centre, global trial
in the 1st-line treatment of recurrent or metastatic HNSCC. The trial tested _Imfinzi_
or _Imfinzi_ plus a second immunotherapy, tremelimumab, versus the EXTREME treatment
regimen (cetuximab with cisplatin or carboplatin plus 5-fluorouracil), a standard
of care treatment. High PD-L1 was defined as either 50% or more tumour cells or 
25% or more tumour-infiltrating immune cells expressing PD-L1.

The trial was conducted in more than 200 centres across 23 countries, including 
centres in the US, Europe, South America and Asia. The primary endpoint was OS in
patients with high PD-L1 expression in the _Imfinzi _monotherapy arm. OS in ‘all-
comer’ patients treated with the combination of _Imfinzi_ plus tremelimumab was 
being tested as a key secondary endpoint.

**Imfinzi**

_Imfinzi _(durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks
the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading
tactics and releasing the inhibition of immune responses.

_Imfinzi_ is approved in the curative-intent setting of unresectable, Stage III 
non-small cell lung cancer (NSCLC) after chemoradiation therapy in the EU, US, Japan,
China and many other countries, based on the PACIFIC Phase III trial. Additionally,
it is approved in the EU, US, Japan and many other countries for the treatment of
extensive-stage small cell lung cancer (SCLC) based on the CASPIAN Phase III trial.
_Imfinzi _is also approved for previously treated patients with advanced bladder
cancer in the US and several other countries.

As part of a broad development programme, _Imfinzi_ is being tested as a monotherapy
and in combination with other anti-cancer treatments for patients with NSCLC, SCLC,
bladder cancer, hepatocellular carcinoma (HCC), biliary tract cancer, oesophageal
cancer, gastric and gastroesophageal cancer, cervical cancer, ovarian cancer, endometrial
cancer and other solid tumours.

> **Dave Fredrickson, Executive Vice President, Oncology Business Unit at AstraZeneca,
> said**: “Metastatic head and neck cancer is a complex and challenging disease 
> with a poor prognosis. While we are disappointed by these results, insights from
> the KESTREL Phase III trial will advance our understanding and application of 
> immunotherapy across our clinical development programme. We will continue to build
> on the established benefits of _Imfinzi_ in early lung cancer and small cell lung
> cancer, to bring immunotherapy treatment options to all patients who may benefit.”

Share on:
